Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a …
S Amadori, S Suciu, R Stasi, HR Salih… - Journal of clinical …, 2013 - ascopubs.org
Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …
Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of …
S Amadori, S Suciu, D Selleslag, F Aversa… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
AK Burnett, NH Russell, RK Hills, J Kell… - Journal of clinical …, 2012 - ascopubs.org
Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients …
S Amadori, S Suciu, D Selleslag, R Stasi… - British journal of …, 2010 - Wiley Online Library
This study compared two schedules of low‐dose gemtuzumab ozogamicin (GO) as induction
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
C Nabhan, LM Rundhaugen, MB Riley, A Rademaker… - Leukemia research, 2005 - Elsevier
The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …
[PDF][PDF] Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a …
S Amadori, S Suciu, R Willemze, F Mandelli… - 2004 - repository.ubn.ru.nl
BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is
associated with low rates of response to conventional chemotherapy and long-term survival …
associated with low rates of response to conventional chemotherapy and long-term survival …
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
S Nand, M Othus, JE Godwin… - Blood, The Journal …, 2013 - ashpublications.org
This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …
[HTML][HTML] Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid …
Background Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy …
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy …
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …
[HTML][HTML] Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed …
S Castaigne, C Pautas, C Terre, E Raffoux… - Blood, 2011 - Elsevier
Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …
相关搜索
- older patients gemtuzumab ozogamicin
- older patients randomized phase
- older patients eortc gimema
- randomized phase eortc gimema
- induction chemotherapy gemtuzumab ozogamicin
- older patients induction chemotherapy
- line therapy leukemia patients
- older patients combination with vorinostat
- randomized phase intensive chemotherapy
- eortc gimema intensive chemotherapy
- citosine arabinoside gemtuzumab ozogamicin
- older patients intensive chemotherapy
- elderly patients gemtuzumab ozogamicin